Compare ResMed Inc. (RMD) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? ResMed Inc. trades at $225 (market cap $32.61B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $60.4. The key difference: ResMed Inc. pays a 1.17% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | VWO | |
|---|---|---|
Market Cap | $32.61B | — |
Sector | Health | — |
52-Week High | $293.73 | $61.24 |
52-Week Low | $182.82 | $51.20 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
VWO, the Vanguard FTSE Emerging Markets ETF, trades at $60.41, up 0.13% on the day, with a bullish technical signal from moving averages and a neutral reading from oscillators. The fund's low expense ratio of 0.06% and focus on emerging markets attract institutional inflows, as seen in recent 13F filings. Recent news highlights strong capital flows into emerging market ETFs and comparisons with peers on cost and diversification.
The outlook for VWO is supported by record inflows and favorable expense ratios, but risks include concentrated exposure to developing economies and currency volatility. Analyst sentiment is generally positive due to diversification benefits and cost efficiency, though geopolitical and economic uncertainties in emerging markets pose significant headwinds for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
